

From: Sista, Ramani V  
Sent: Monday, February 09, 2015 10:45 AM  
To: 'Heather Pratt'  
Subject: RE: NDA 125552 - IR-(b) (4) Inoculum Information Attached

Importance: High

Hi Heather,  
Unfortunately, this is not the information the reviewer is looking for.

When B&F test of CPD solution was performed, (b) (4)

. You are supposed to (b) (4)

. We want to see the  
results  
of (b) (4) (in other words (b) (4)).

Please provide this information latest by COB Friday, February 13.

Thanks,  
Ramani

Ramani Sista, PhD, RAC, CQA  
RPM

OCTGT/CBER/FDA

Phone: 240 402 8354

THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED  
AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED  
FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to  
deliver

the document to the addressee, you are hereby notified that any review, disclosure,  
dissemination, copying, or other action based on the content of this communication  
is not

authorized. If you have received this document in error, please immediately notify  
the sender  
immediately by e-mail or phone.

From: Heather Pratt [mailto:heather@macopharmausa.com]

Sent: Monday, February 02, 2015 4:39 PM

To: Sista, Ramani V

Subject: NDA 125552 - IR-(b) (4) Inoculum Information Attached

Dear Ramani,

As requested, please find attached the Lyophilized Microorganism Specification and  
Performance

Certificates for the microorganisms used in the sterility test validation and

(b) (4) results. The  
recovery is stated on the certificate.

Thanks,  
Heather

Best Regards,

Heather Pratt

Listen • Understand  
• Provide Solutions

Heather Pratt  
Manager, Regulatory & Clinical  
Affairs

heather@macopharmausa.com

3675 Crestwood Pkwy  
Suite 260  
Duluth, GA 30096  
Main: 770-270-6867 x102  
Cell: 404-428-1663  
Fax: 770-496-9835

From: Sista, Ramani V [mailto:Ramani.Sista@fda.hhs.gov]  
Sent: Thursday, January 29, 2015 2:16 PM  
To: Heather Pratt  
Subject: RE: NDA 125552 - IR-Sterility Testing Attached for Reference MSC1207DD English Translation Attached

Hi Heather,  
Any updates on the (b) (4) inoculum results associated to the report you sent in the email below?  
Thanks,  
Ramani

Ramani Sista, PhD, RAC, CQA  
RPM

OCTGT/CBER/FDA

Phone: 240 402 8354

THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver

the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.

From: Heather Pratt [mailto:heather@macopharmausa.com]  
Sent: Thursday, January 22, 2015 2:06 PM  
To: Sista, Ramani V  
Subject: NDA 125552 - IR-Sterility Testing Attached for Reference MSC1207DD English Translation Attached

Dear Ramani,

Please find attached the English translation of the Sterility Testing for (b) (4) batches of MSC1207DD at T0 and T18 months.

We hope to have the inoculum (b) (4) results from the supplier soon as well.

Thanks,  
Heather

Best Regards,

Heather Pratt

Listen • Understand  
• Provide Solutions

Heather Pratt  
Manager, Regulatory & Clinical  
Affairs  
heather@macopharmausa.com

3675 Crestwood Pkwy  
Suite 260  
Duluth, GA 30096  
Main: 770-270-6867 x102  
Cell: 404-428-1663  
Fax: 770-496-9835

From: Heather Pratt  
Sent: Monday, January 19, 2015 5:57 PM  
To: 'Sista, Ramani V'  
Subject: RE: NDA 125552 - IR-Sterility Testing Attached for Reference MSC1207DD

Dear Ramani,

Please find attached the Sterility Testing results for (b) (4) batches of MSC1207DD at T0 and T18 months. These are the conformance lots since there is no routine production as yet. Kindly note, the document is in French and Polish. I have put in a rush order to have the document translated and will forward as soon as it is received. I hope by Wednesday.

In regards to the inoculum (b) (4) results, we are waiting on some information from our supplier and will provide that response as soon as we receive it.

Thanks,  
Heather

Best Regards,

Heather Pratt

Listen • Understand  
• Provide Solutions

Heather Pratt  
Manager, Regulatory & Clinical  
Affairs  
heather@macopharmausa.com

3675 Crestwood Pkwy  
Suite 260  
Duluth, GA 30096  
Main: 770-270-6867 x102  
Cell: 404-428-1663  
Fax: 770-496-9835

From: Sista, Ramani V [mailto:Ramani.Sista@fda.hhs.gov]  
Sent: Thursday, January 15, 2015 10:04 AM  
To: Heather Pratt  
Subject: RE: NDA 125552 - IR  
Importance: High

Hi Heather,  
The reviewer is looking for information below regarding the attached:

Conformance lots are lots manufactured in support of the BLA application. If you have sterility results on any lots of collection bags for MSC1207DD and MSC1208DD, that would work.

The attached sterility test validation submitted for sterility test was translated from Polish and looks like missed some information. Could you please ask for the clarification?

1. Please confirm the inoculum/ colony forming units for each microorganism used in sterility test validation (protocol no. (b) (4) 01);
2. Please provide (b) (4) results for microorganisms used in the sterility test validation.

Thanks,  
Ramani  
Ramani Sista, PhD, RAC, COA  
RPM  
OCTGT/CBER/FDA  
Phone: 240 402 8354

THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.

From: Heather Pratt [mailto:heather@macopharmausa.com]  
Sent: Wednesday, January 14, 2015 2:55 PM  
To: Sista, Ramani V  
Subject: RE: NDA 125552 - IR

Dear Ramani,

I received your email below requesting sterility test results, however, can you please clarify what you mean by "conformance lots"?

Thanks,  
Heather

Best Regards,

Heather Pratt

Listen • Understand  
• Provide Solutions

Heather Pratt  
Manager, Regulatory & Clinical  
Affairs  
heather@macopharmausa.com

3675 Crestwood Pkwy  
Suite 260  
Duluth, GA 30096  
Main: 770-270-6867 x102  
Cell: 404-428-1663  
Fax: 770-496-9835

From: Sista, Ramani V [mailto:Ramani.Sista@fda.hhs.gov]  
Sent: Wednesday, January 14, 2015 10:39 AM  
To: Heather Pratt  
Subject: NDA 125552 - IR  
Importance: High

Hi Heather,  
Please provide the information below by COB tomorrow.

Please provide sterility test results of conformance lots for cord blood sterile collection bags with anticoagulant Citrate Phosphate Dextrose (CPD).

Please let me know if you have questions.  
Thanks,  
Ramani

Ramani Sista, PhD, RAC, CQA  
RPM  
Office of Cellular Tissue & Gene Therapies  
CBER, FDA  
Phone: 240 402  
8354

Ramani.Sista@fda.hhs.gov  
THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.